File(s) not publicly available
Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D.
This paper explores how changes in genetics, database, high-throughput screening and bioinformatics technologies have allowed pharmaceutical firms to exploit economies of scale in experimentation. Traditional craft-based, sequential experimentation in chemistry and biology has been complemented by firstly, the automated, mass-production analysis of populations and secondly, by 'in silico' experimentation using simulations and databases. The changes are analysed within a Chandlerian framework that highlights how increases in the 'throughput' of R&D are dependent on organizational and managerial responses to systemic uncertainty.
History
Publication status
- Published
Journal
Industrial and Corporate ChangeISSN
0960-6491Publisher
Industrial and Corporate ChangeExternal DOI
Issue
2Volume
9Page range
315-359ISBN
0960-6491Department affiliated with
- SPRU - Science Policy Research Unit Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-02-06Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC